Blue Owl Capital Holdings LP Purchases New Stake in Oric Pharmaceuticals, Inc. $ORIC

Blue Owl Capital Holdings LP purchased a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 515,000 shares of the company’s stock, valued at approximately $4,213,000. Oric Pharmaceuticals accounts for about 0.3% of Blue Owl Capital Holdings LP’s holdings, making the stock its 26th largest holding.

Other hedge funds have also recently bought and sold shares of the company. Royce & Associates LP grew its position in Oric Pharmaceuticals by 521.2% in the third quarter. Royce & Associates LP now owns 1,458,483 shares of the company’s stock valued at $17,502,000 after acquiring an additional 1,223,709 shares in the last quarter. UBS Group AG grew its position in Oric Pharmaceuticals by 116.6% in the fourth quarter. UBS Group AG now owns 734,858 shares of the company’s stock valued at $6,011,000 after acquiring an additional 395,622 shares in the last quarter. Rafferty Asset Management LLC grew its position in Oric Pharmaceuticals by 100.7% in the third quarter. Rafferty Asset Management LLC now owns 85,592 shares of the company’s stock valued at $1,027,000 after acquiring an additional 42,948 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Oric Pharmaceuticals in the fourth quarter valued at approximately $135,000. Finally, SG Americas Securities LLC grew its position in Oric Pharmaceuticals by 127.6% in the fourth quarter. SG Americas Securities LLC now owns 41,016 shares of the company’s stock valued at $336,000 after acquiring an additional 22,993 shares in the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on ORIC. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Oric Pharmaceuticals in a research report on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Tuesday, April 21st. The Goldman Sachs Group raised shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Friday, May 15th. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of Oric Pharmaceuticals in a research report on Tuesday, February 24th. Finally, Wall Street Zen downgraded shares of Oric Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.36.

Insider Buying and Selling at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 52,000 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the sale, the chief financial officer directly owned 68,148 shares in the company, valued at $920,679.48. The trade was a 43.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.70% of the stock is currently owned by corporate insiders.

Oric Pharmaceuticals Price Performance

Shares of ORIC opened at $8.32 on Monday. The business’s fifty day moving average price is $10.04 and its 200 day moving average price is $10.59. Oric Pharmaceuticals, Inc. has a 12-month low of $5.51 and a 12-month high of $14.93. The stock has a market capitalization of $861.29 million, a PE ratio of -5.78 and a beta of 1.11.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). As a group, research analysts anticipate that Oric Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Oric Pharmaceuticals Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.